Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Filgrastim Hospira (Nivestym) vs Neupogen in Healthy Volunteers
NCT02923791Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Pfizer. Primary endpoint: Incidence of Anti-Drug Antibodies at 62 days. Started Oct 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02923791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923791.